Antifungal Prophylaxis With Posaconazole Is Effective in Preventing Invasive Fungal Infections in Acute Myeloid Leukemia Patients During Induction and Salvage Chemotherapy
Open Access
- 2 July 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 61 (8) , 1351-1352
- https://doi.org/10.1093/cid/civ542
Abstract
To the Editor—Pagano et al [1] analyzed the efficacy of antifungal prophylaxis with posaconazole and itraconazole in acute myeloid leukemia (AML) patients receiving induction chemotherapy. There were significant differences in the percentage of breakthrough proven/probable mold infections (posaconazole 2.7% vs itraconazole 10.7%; P = .02). The authors concluded that posaconazole prophylaxis conferred an advantage for breakthrough invasive fungal disease and overall survival compared with itraconazole (P = .002).Keywords
This publication has 2 references indexed in Scilit:
- Evaluation of the Practice of Antifungal Prophylaxis Use in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results From the SEIFEM 2010-B RegistryClinical Infectious Diseases, 2012
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupClinical Infectious Diseases, 2008